文献速递炎症性肠病

综述:接受小分子药物治疗的炎症性肠病患者心血管事件风险

Review article: Risk of cardiovascular events in patients with inflammatory bowel disease receiving small molecule drugs.
PubMed 文献 · Aliment Pharmacol Ther · 2023-04-10

该综述由心血管疾病与炎症性肠病(IBD)领域专家共同撰写,回顾已发表文献,评估JAK抑制剂和S1P受体调节剂等小分子药物治疗中重度IBD时的心血管事件风险,并给出降低风险的实用建议。现有证据未显示托法替布及其他JAK抑制剂在整体IBD人群中增加心血管事件风险,但中等至高心血管风险患者风险较高;S1P调节剂可能与剂量依赖的首剂效应及短暂传导异常风险相关。

要点

  • IBD人群证据未显示托法替布及其他JAK抑制剂增加心血管事件风险。
  • 中等至高心血管风险患者使用JAK抑制剂时心血管事件风险较高。
  • S1P调节剂可能与剂量依赖的首剂效应及短暂传导异常风险相关。

核心结论

  • 现有JAK抑制剂和S1P调节剂的证据表明,从心血管角度看,小分子药物在整体IBD人群中具有令人安心的安全性特征。
  • 应努力识别心血管事件风险较高的IBD患者。

研究设计与样本

  • 综述已发表文献,建议由心血管疾病和IBD领域的专家综合形成。

主要发现

  • 来自IBD人群的证据未显示托法替布及其他JAK抑制剂增加心血管事件风险。
  • 中等至高心血管风险患者中风险较高。
  • S1P调节剂可能与剂量依赖的、首剂效应相关的短暂传导异常风险有关,包括心动过缓和房室传导阻滞。

关键数值与推荐

  • 所有IBD患者应筛查和监测心血管危险因素。
  • 开始小分子药物治疗前应进行心血管疾病风险分层。

临床怎么用

  • 所有IBD患者应筛查和监测心血管危险因素。
  • 开始小分子药物治疗前应进行心血管疾病风险分层。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: In the context of an ageing inflammatory bowel disease (IBD) population, cardiovascular comorbidities become particularly relevant. Novel small molecule drugs (SMDs) for the treatment of moderate-to-severe IBD have been recently approved, including Janus kinase (JAK) inhibitors and sphingosine-1-phosphate receptor (S1P) modulators. Data from rheumatoid arthritis population have raised concerns about the risk of cardiovascular events with the use of tofacitinib, which was extrapolated to other immune-mediated diseases and other JAK inhibitors. S1P receptor modulation has been associated with potential cardiovascular events, especially bradycardia and cardiac conduction abnormalities. AIM: To review the incidence of cardiovascular events with the use of SMDs in patients with IBD and to provide practical recommendations on mitigation strategies. METHODS: Published literature was reviewed; recommendations were synthesised by experts in both cardiovascular diseases and IBD. RESULTS: Evidence from the IBD population does not indicate a higher risk of cardiovascular events with tofacitinib and other JAK inhibitors. The risk is higher in patients with intermediate to high cardiovascular risk. S1P modulators may be associated with a dose-dependent, first-dose effect, transient risk of conduction abnormalities (bradycardia and AV block). Screening and monitoring of cardiovascular risk factors should be done in all patients with IBD. Risk stratification for cardiovascular disease should be performed before starting treatment with SMDs. CONCLUSIONS: Available evidence of both JAK inhibitors and S1P modulators indicates a reassuring safety profile of SMDs from the cardiovascular perspective in the overall IBD population. Efforts should be made to identify patients with IBD at a higher risk of cardiovascular events.

来源:Aliment Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. Olivera PA, Lasa JS, Peretto G, et al. Review article: Risk of cardiovascular events in patients with inflammatory bowel disease receiving small molecule drugs. Aliment Pharmacol Ther. 2023. PMID: 37038269. doi:10.1111/apt.17509

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。